Gonadotrophin dynamics during reproductive life

Menstrual cycles of 30 patients with juvenile systemic lupus erythematosus (JSLE) were compared with 30 age-matched controls. The mean age of patients with JSLE and controls was similar (17.4 +/- 3.2 vs 17.06 +/- 2.08 years, P = 0.66). The mean menarche age was higher in JSLE than controls (13.13 +/- 1.4 vs 11.56 +/- 1.5 years, P = 0.0008). On the contrary, the mean maternal menarche age was similar in both groups (P = 0.62). Menstrual abnormalities and longer length cycles were more frequently observed in JSLE than controls (63% vs 10%, P = 0.0001; 23% vs 0%, P = 0.0105, respectively). The median of follicle stimulating hormone was significantly higher in patients with JSLE compared with controls (4.6 vs 3.4 IU/L, P = 0.0207), and the median of progesterone was lower (32.5 vs 70 ng/mL, P = 0.0033). The median of luteinizing hormone was lower in patients with JSLE with menstrual abnormalities versus normal cycles (2.9 vs 5.5 IU/L, P = 0.019) and both had a high percentage of decreased progesterone levels (63% vs 73%, P = 0.70). Our findings support the notion that menstrual disturbances are frequent and may be associated with pituitary dysfunction leading to a decreased progesterone production. We also reported that in spite of premature ovarian failure being a rare event in JSLE the follicular reserve seems to be low regardless of intravenous cyclophosphamide treatment.

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 97%

Menstrual and hormonal alterations in juvenile systemic lupus erythematosus

Medeiros

Febrônio

Bonfá

et al. 2009

“…A possible explanation for the discrepant findings in the above mentioned studies 8,11,39 could be the higher mean age of the patients evaluated in the North American study and that most of these patients were exposed to cyclophosphamide after the onset of puberty. Thus, because laboratory markers are available and accepted sensitive marker of ovarian reserve, 49 we recommend that the ovarian reserve of females who have been treated with alkylating therapy for jSLE is assessed.…”

Section: Preservation Of Male Fertilitymentioning

confidence: 99%

Review: Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus

Silva

Brunner

2007

Increased survival of children with juvenile systemic lupus erythematosus (jSLE) and improved prognosis have led to a change in the long-term health issues arising for jSLE patients. Preservation of gonadal functioning and fertility are of increasing importance for young adults with jSLE. Events during childhood, such as exposure to alkylating agents, may compromise the reproductive potential. Even in the absence of gonadotoxic therapies, fertility may be decreased through organs specific involvement with jSLE. Strategies to preserve the reproductive potential of girl and boys with jSLE are discussed.

“…3 This menstrual disturbance was reported by Schaller in approximately one fourth of adolescent JSLE, 2 a frequency higher than that observed in the present cohort, probably reflecting a more effective early recognition and treatment of these patients in the last three decades. 24 Remarkably, ovarian follicular reserves in all JSLE patients were still adequate as demonstrated by normal serum FSH level, the most sensitive marker of ovarian function, 25,26 despite IVCYC use in approximately half of these patients. In contrast, this drug is a wellestablished cause of amenorrhea and POF in adults with lupus.…”

mentioning

confidence: 97%

Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicentre cohort study

Silva

Hilário

Febrônio

et al. 2007

We evaluated the prevalence and clinical associations of amenorrhea in 298 female juvenile systemic lupus erythematosus (JSLE) patients (ACR criteria) followed in 12 Brazilian Paediatric Rheumatology centres. Amenorrhea was observed in 35 patients (11.7%) with a mean duration of 7.2 +/- 3.6 months. The hormones were performed in 32/35 patients and none of them had FSH and LH levels above and estradiol below the normal range according to pubertal changes. JSLE patients with amenorrhea were younger (15.04 +/- 2.5 versus 17.8 +/- 3.1 years; P = 0.001), and had a shorter period of time between menarche and current age (3.4 +/- 2.9 versus 6.7 +/- 5.4 years; P = 0.001). Interestingly, the frequency, cumulative dose, number of pulses and duration of intravenous cyclophosphamide treatment were alike in patients with and without amenorrhea (P > 0.05). In contrast, patients with amenorrhea had significantly higher SLEDAI (P = 0.01) and SLICC/ACR-DI (P = 0.024) scores compared to those without this condition. Independent risk factors identified by multivariate analysis were higher SLEDAI (OR = 1.059; CI = 1.004-1.116; P = 0.034) and SLICC/ACR-DI (OR = 2.125; IC = 1.373-3.291; P = 0.001) scores. Our data suggest that in spite of immunosuppressive therapy, JSLE patients have an adequate ovarian follicular reserve and amenorrhea is particularly associated with disease activity and damage.